Companion Animal Vaccines Market - By Vaccine Type, By Animal Type, By Route of Administration, By Distribution Channel - Global Forecast 2025 - 2034

Companion Animal Vaccines Market Size

The global companion animal vaccines market was valued at USD 3.5 billion in 2024. The market is anticipated to grow from USD 3.7 billion in 2025 to USD 6.4 billion in 2034, growing at a CAGR of 6.5%. The market of companion animal vaccines is experiencing rapid growth due to the growing population of pets and increasing pet ownership across the world.
 

With increasing number of households adopting pets, there is also a consequent demand for preventive healthcare services such as vaccinations that help safeguard pets from infectious diseases. This scenario is more prominent in the developed regions of North America and Europe, where pet humanization is driving higher spending on veterinary services. For instance, pet ownership in the U.S. has jumped significantly over the past three decades. As of 2024, 66% of U.S. households, that is approximately 86.9 million homes, own a pet. Also, emerging markets in Asia and Latin America are witnessing increased pet adoption rates, further fueling the demand for companion animal vaccines.
 

Additionally, development of innovative technologies is another major growth driver for the companion animal vaccines market. The development of recombinant vaccines, DNA vaccines, along with vector-based vaccines are improving the safety and efficacy of immunization. These next-generation vaccines offer longer-lasting immunity and fewer side effects compared to traditional vaccines.
 

Furthermore, regulatory efforts together with strategic disease control programs are aiding in the expansion of the market. The vaccination policies and education programs designed to prevent the spread of zoonotic and infectious diseases are being put into action by governments and pet healthcare institutions globally. For instance, rabies vaccination programs have significantly decreased the disease prevalence in pets which helps reduce the risk of humans contracting it. In addition, the growing partnerships of veterinary associations with vaccine manufacturers are increasing the supply and distribution of vaccines so that more companion animals are immunized. All these factors are anticipated to drive the adoption of vaccines in companion animals globally, thus propelling the market growth over the forecast years.
 

Companion animal vaccines are biological products intended to induce the immune response of pets like dogs and cats to defend against infectious diseases. Companion animal vaccines are very critical in the health promotion and well-being of pets, decreasing disease spread, and safeguarding public health by mitigating zoonotic risks.
 

Companion Animal Vaccines Market Trends

• One of the key market trends is the growing pet ownership alongside the humanization of pets. As per the 2024 Global Pet Parent Study estimates the global pet population at around 1 billion. Families in the U.S., Brazil, EU, and China alone account for over half a billion dogs and cats, while more than half the world is estimated to have a pet at home. People are treating their pets as family which has increased spending on preventive healthcare like routine vaccinations.
   
• Growing number of insured pets is a significant driver of the market. Pet insurance coverage has been steadily increasing as owners recognize the importance of safeguarding their animals’ health and reducing the financial burden of veterinary care.
   
• This trend is particularly evident in regions with a high penetration of pet insurance, such as North America and parts of Europe. With insurance plans covering routine vaccinations as a preventive measure, more pet owners are opting for timely immunizations, ensuring higher vaccination rates.
   
• The companion animal vaccine market is seeing the emergence of modern vaccines that include DNA vaccines, recombinant vaccines, and vector vaccines that are much more effective and provide longer-lasting immunity with fewer side effects than older vaccines.
   
• There are also new methods of administering vaccines such as needle-free systems and oral formulations, which enhance compliance with the instruction, making life easier for veterinarians and pet owners. For instance, in May 2022, Pulse NeedleFree Systems, a leading supplier of needle-free delivery technologies to the animal health industry, introduced disposable line of needle-free livestock vaccination devices.
   
• Further, the increased occurrence of zoonotic disease is one of the major factors accelerating the adoption of companion animal vaccines. Diseases such as rabies, leptospirosis, and Lyme disease pose immense risks to public health. For example, as per the CDC, every year, rabies kills 70,000 people worldwide. Dogs cause 99% of human rabies deaths outside the U.S. Animal vaccines such as rabies vaccine, play an important role in curbing the spread of such infectious diseases.
   
• Several initiatives by government and non-government bodies towards better animal welfare and safety, propel the market growth. For instance, the Livestock Health and Diseases Control (LH&DC) scheme is a Centrally Sponsored Scheme (CSS) implemented by the Department of Animal Husbandry and Dairying (DAHD), India, to improve animal health and productivity, by implementation of prophylactic vaccination programs against various diseases of livestock and poultry. Such initiatives aimed at improving animal health benefit market growth.
   

Companion Animal Vaccines Market Analysis

Based on the vaccine type, the global market is segmented into attenuated live vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, recombinant vaccine, and other vaccine types. The attenuated live vaccine segment dominated the market and was valued at USD 1.5 billion in 2024.
 

• High adoption of attenuated live vaccines in companion animals is primarily due to its strong immune response, long-lasting immunity, and cost-effectiveness. These vaccines have live but weakened pathogens that evoke a strong immune response in companion animals, thus reducing the need for frequent booster doses.
   
• Also, attenuated live vaccines are widely used in both livestock and companion animals due to their efficacy in preventing a broad range of diseases, including highly contagious ones. Their relatively low production costs and widespread availability further support their leading position in the market.
   
• Live attenuated vaccines are highly preferred in emerging economies owing to high cost-effectivity as compared to other vaccines. Thus, numerous benefits mentioned above are propelling the market growth positively.
   

Based on the animal type, the global companion animal vaccines market is categorized into canine, feline, equine, and avian. The canine segment accounted for the highest market share of 53.4% in 2024.
 

• The increasing segmental growth is attributed to the rising adoption rate of dogs as companion animals, coupled with growing expenditure on dogs. For instance, in 2021, according to the American Pet Products Association (APPA), 90.5 million families own a pet in the U.S. among which 69 million (over 76%) households own a dog.
   
• Also, countries in Europe such as U.K, Poland, France are noted to have some of the highest population of pet dogs that attracts more pet owners to opt for various core and non-core vaccines.
   
• Thus, the countries with high population of dogs as compared to other companion animals is expected to create a considerable growth opportunity for the overall growth of market.
   
• Moreover, the increasing focus of manufacturers on development of canine vaccines to meet the growing demand is set to further propel market growth.
   

Based on the route of administration, the global companion animal vaccines market is categorized into parenteral, oral, and nasal. The parenteral segment dominated the market in 2024 and is anticipated to grow at a CAGR of 6.2% between 2025 – 2034.
 

• The parenteral segment dominates the market due to high efficacy, long term immunity, and strong immune response.
   
• Parenteral vaccines, given through intramuscular or subcutaneous injection, have precise dosing and controlled antigen exposure, therefore minimizing variability in dose-dependent immune response.
   
• This segment is also supported by strong adoption from veterinary clinics and hospitals. Parenteral route of administration is the most preferred among veterinary practitioners because of its high efficacy and well-established safety profile.
   
• Increased demand for combination vaccines that are mostly offered in injectable forms is one more factor that increases the market share for the parenteral segment.
   
• Additionally, advancements in adjuvant technology have improved the immunogenicity of injectable vaccines, allowing for less frequent booster doses. The segment also benefits from strong manufacturer preference, because injectable formulations are thought to be more stable and have a longer shelf life than oral or intranasal ones.
   

Based on the distribution channel, the global companion animal vaccines market is categorized into veterinary hospital pharmacies, retail pharmacies, and online pharmacies. The veterinary hospital pharmacies segment is anticipated to witness high growth to reach USD 3.4 billion by 2034.
 

• Veterinary hospital pharmacies are equipped with a wide range of vaccines and have the advantage of being directly accessible to veterinary professionals.
   
• Increasing number of pet owners seeking regular veterinary care and vaccination for their animals, coupled with the rising awareness about preventive healthcare, further contributes to the growth of this segment.
   
• Moreover, the ability of veterinary hospital pharmacies to offer tailored vaccination schedules and foster long-term relationships with pet owners enhances their prominence in the market.
   
• These pharmacies offer professional consultations that ensure the right vaccines are administered according to animal health needs, which further boosts their market share in the market.
   

North America companion animal vaccines market held the largest market share of 40.5% in 2024 in the global market, and it is anticipated to expand at a 6% CAGR over the forecast period.
 

The U.S. market was valued at USD 1.14 billion in 2021. The market size was valued at USD 1.18 billion in 2022 and reached USD 1.23 billion in 2023.
 

• High rates of pet ownerships in the country coupled with availability of advanced animal vaccines drives the market growth. The growing humanization of pets in the U.S. also increases spending on preventive veterinary care, including routine vaccinations.
   
• According to the 2021–2022 National Pet Owners Survey by the American Pet Products Association (APPA), 70% of the U.S. households owned at least one type of pet. Similarly, almost 69 million of the U.S. households have at least one dog, and 45.3 million have at least one cat, about 9.9 million have birds, and 3.5 million have horses.
   
• Such high volume of pets in the country increases the demand for companion animal vaccines.
   
• The U.S. market is further strengthened by the presence of major companies such as Zoetis, Merck Animal Health, and Elanco which ensure a constant supply of advanced and effective vaccines for pets.
   

Europe companion animal vaccines market was valued at USD 967.9 million in 2024.
 

• Europe's robust infrastructure in veterinary healthcare, high pet ownership, and strict pet vaccination policies contribute to high regional market growth.
   
• Recent reports published by FEDIAF and GlobalPETS reveal that Europe is home to approximately 352 million pets across various species. Cats and dogs dominate the pet population, with 129 million cats and 106 million dogs, respectively.
   
• Countries such as Germany, France, and UK have strong policies which routinely mandate vaccinations for rabies, canine distemper, and feline leukemia that propels demand for these vaccines.
   
• Also, the presence of key market players such as Boehringer Ingelheim, Elanco, and Virbac reinforces Europe’s strength in the market. These companies are actively participating in innovation through the development of innovative vaccines, thereby aiding in market growth.
   

UK exhibits strong growth potential in the Europe companion animal vaccines market.
 

• UK holds a substantial share in the Europe market due to strong culture of pet ownership, developed veterinary services, and high concern for health issues related to animals.
   
• As per the PDSA Animal Wellbeing Report 2024, 51% of UK adults own a pet. Of which, 28% of UK adults have a dog and 24% of adults have a cat. Such large number of companion animals create an ever-increasing demand for preventive healthcare services like vaccination.
   
• The market growth is also supported by government initiatives and regulations related to pet vaccination, as well as strict animal health policies.
   

The Asia Pacific companion animal vaccines market in is estimated to grow at a CAGR of 7.2% over the analysis period. China presents significant growth potential in the market.
 

• The market for companion animal vaccines in China is witnessing strong growth opportunities owing to the surge in pet ownership.
   
• For example, pet ownership in China has seen a notable rise in recent years, reflecting changing societal values and lifestyles. According to a report by the Chinese Pet Industry Association in 2023, over 60% of urban households now have pets, up from 48% in 2021.
   
• This increase signifies a growing affinity for pets as family members, particularly among younger generations. As the pet population rises, the demand for companion animal vaccines also increases, thereby aiding in market growth.
   
• Further, the growing burden of zoonotic diseases such as rabies and canine distemper is also increasing the focus on vaccination programs, which is advantageous to the market.
   
• In addition, rapidly expanding veterinary infrastructure in the country such as veterinary hospitals and clinics will further enhance the market growth.
   

Brazil presents a significant growth opportunities in the companion animal vaccines market, driven by its large and growing pet population, increasing pet ownership, and rising awareness about animal health.
 

• Brazil has the third-largest pet population in the world with 160 million pets, of which 60 million are dogs, 30 million cats, and 32 million pet-owning households.
   
• Such high pet volume coupled with strong growth in veterinary expenditure is anticipated to foster the market growth.
   
• Also, increased disposable income and the perception of pets as family members is increasing the expenditure on pet healthcare, including vaccinations.
   
• Further, rising government initiatives to boost animal welfare and support business in veterinary industry aid in the country level market growth.
   

Companion Animal Vaccines Market Share

The market is highly competitive, with several key companies striving to develop novel formulations in the market. Several major organizations, local small players, and start-ups joining the industry competition. Top 6 companies in the market such as Zoetis, Elanco Animal Health, Merck Animal Health, Virbac, Vetoquinol, and Boehringer Ingelheim International account for approximately 60 – 70% of the global market share. These players continuously invest in new vaccine development, including recombinant and DNA-based vaccines, to enhance efficacy and safety.
 

Additionally, there are several local and regional players operating in the market are boosting competition by providing affordable options at lower costs. These players are also involved in several strategies such as mergers, acquisitions, and novel product launches to expand their product offerings. For instance, in September 2024, Bioveta, a.s., in partnership with Vetina Healthcare LLP, has launched the Biocan NOVEL canine vaccine range in India. This versatile vaccine is designed to protect dogs against lethal infections such as rabies and leptospirosis, which pose significant risks not only to dogs but also to humans and other animals. Such initiatives by market players enhances the competitive landscape in the market, thereby boosting the market growth.
 

Companion Animal Vaccines Market Companies

Few of the prominent players operating in the companion animal vaccines industry include:

• Boehringer Ingelheim International
• Brilliant Bio Pharma
• Bioveta
• Biogenesis Bago
• Ceva Sante Animale
• Durvet
• Elanco Animal Health
• HIPRA
• Indian Immunologicals
• Merck Animal Health
• Sinovac 
• Vetoquinol
• Virbac
• Zoetis
   

Elanco Animal Health is a key player in the companion animal vaccines market, offering a range of vaccines for disease prevention in pets. The company's portfolio includes vaccines targeting rabies, leptospirosis, Bordetella, and other infectious diseases, supporting pet health and veterinary care worldwide.
 

Zoetis is a leading player in the market, offering a broad portfolio of vaccines for dogs and cats, and other companion animals. The company invests in R&D to develop advanced biologics and innovative vaccine technologies, strengthening its market position globally.
 

Companion Animal Vaccines Industry News

• In January 2025, Bioveta introduced new vaccines at a seminar in Bangladesh, marking a significant step in the country's rapidly growing pet animal care sector. The new vaccines launched include Biofel and Biocan Novel, which are specifically designed for use in local clinics specializing in pet animal care.
   
• In September 2024, Boehringer Ingelheim acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic diseases in pets. With the acquisition, Boehringer Ingelheim strengthens its animal health research and development (R&D) pipeline, specifically in the fast-growing pet therapeutics category.
   
• In June 2021, Zoetis announced a collaboration with Canine Companions for Independence (CCI) to provide vaccines and other healthcare products to service dogs. This strategic engagement helped the company in strengthening its product offerings with respect to canine vaccines.
   
• In April 2021, Boehringer Ingelheim announced the launch of Feligen RCPCh, a new vaccine for cats that protects against several infectious diseases, including feline herpesvirus and calicivirus. This product launch helped the firm to bolster its position in the feline vaccine offerings and offered a competitive advantage.
   

The companion animal vaccines market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Attenuated live vaccine
• Conjugate vaccine
• Inactivated vaccine
• DNA vaccine
• Recombinant vaccine
• Other vaccine types

Market, By Animal Type

• Canine
• Feline
• Equine
• Avian

Market, By Route of Administration

• Parenteral
• Oral
• Nasal

Market, By Distribution Channel

• Veterinary hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE